BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xie Y, Jiang Y, Yang XB, Wang AQ, Zheng YC, Wan XS, Sang XT, Wang K, Zhang DD, Xu JJ, Li FG, Zhao HT. Response of BRCA1-mutated gallbladder cancer to olaparib: A case report. World J Gastroenterol 2016; 22(46): 10254-10259 [PMID: 28028375 DOI: 10.3748/wjg.v22.i46.10254] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Li M, Mou Y, Hou S, Cao D, Li A. Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report. Medicine (Baltimore) 2018;97:e13113. [PMID: 30407325 DOI: 10.1097/MD.0000000000013113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
2 Li X, Gao L, Qiu M, Cao D. Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation. Onco Targets Ther 2021;14:2815-9. [PMID: 33911878 DOI: 10.2147/OTT.S303594] [Reference Citation Analysis]
3 Bagal B, Kumar R, Gaur T, Talreja V, Bonda A, Patkar N, Shetty D, Kowtal P, Subramanian PG, Gupta S, Sarin R, Hasan SK. Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy. Med Oncol 2020;37:48. [PMID: 32277283 DOI: 10.1007/s12032-020-01371-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Hewitt DB, Brown ZJ, Pawlik TM. Surgical management of intrahepatic cholangiocarcinoma. Expert Rev Anticancer Ther 2021;:1-12. [PMID: 34730474 DOI: 10.1080/14737140.2022.1999809] [Reference Citation Analysis]
5 Mehta R, Wood AC, Yu J, Kim R. Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies. Expert Opin Investig Drugs 2021;30:451-61. [PMID: 33660569 DOI: 10.1080/13543784.2021.1898586] [Reference Citation Analysis]
6 Okamura R, Kurzrock R, Mallory RJ, Fanta PT, Burgoyne AM, Clary BM, Kato S, Sicklick JK. Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. Int J Cancer. 2021;148:702-712. [PMID: 32700810 DOI: 10.1002/ijc.33230] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
7 Al-Taee A, Gill A, Mahon S, Lai J, Jallad B. Gallbladder Adenocarcinoma as the First Manifestation of Germline BRCA1 Mutation. J Gastrointest Cancer 2019;50:147-50. [PMID: 28785956 DOI: 10.1007/s12029-017-9995-9] [Reference Citation Analysis]
8 Lin J, Dong K, Bai Y, Zhao S, Dong Y, Shi J, Shi W, Long J, Yang X, Wang D, Yang X, Zhao L, Hu K, Pan J, Sang X, Wang K, Zhao H. Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice. Ann Transl Med 2019;7:467. [PMID: 31700903 DOI: 10.21037/atm.2019.08.67] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
9 Bogenberger JM, DeLeon TT, Arora M, Ahn DH, Borad MJ. Emerging role of precision medicine in biliary tract cancers. NPJ Precis Oncol 2018;2:21. [PMID: 30302397 DOI: 10.1038/s41698-018-0064-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
10 Spizzo G, Puccini A, Xiu J, Goldberg RM, Grothey A, Shields AF, Arora SP, Khushman M, Salem ME, Battaglin F, Baca Y, El-Deiry WS, Philip PA, Nassem M, Hall M, Marshall JL, Kocher F, Amann A, Wolf D, Korn WM, Lenz HJ, Seeber A. Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open 2020;5:e000682. [PMID: 32576609 DOI: 10.1136/esmoopen-2020-000682] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 22.0] [Reference Citation Analysis]
11 Mondaca S, Nervi B, Pinto M, Abou-Alfa GK. Biliary tract cancer prognostic and predictive genomics. Chin Clin Oncol 2019;8:42. [PMID: 31431036 DOI: 10.21037/cco.2019.07.06] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Ricci AD, Rizzo A, Bonucci C, Tober N, Palloni A, Mollica V, Maggio I, Deserti M, Tavolari S, Brandi G. PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block? Medicines (Basel) 2020;7:E54. [PMID: 32878011 DOI: 10.3390/medicines7090054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
13 Adeva J, Sangro B, Salati M, Edeline J, La Casta A, Bittoni A, Berardi R, Bruix J, Valle JW. Medical treatment for cholangiocarcinoma. Liver Int 2019;39:123-42. [DOI: 10.1111/liv.14100] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 16.5] [Reference Citation Analysis]
14 Bezrookove V, Patino JM, Nosrati M, Desprez PY, McAllister S, Soroceanu L, Baron A, Osorio R, Kashani-Sabet M, Dar AA. Niraparib Suppresses Cholangiocarcinoma Tumor Growth by Inducing Oxidative and Replication Stress. Cancers (Basel) 2021;13:4405. [PMID: 34503215 DOI: 10.3390/cancers13174405] [Reference Citation Analysis]